Literature DB >> 1624256

Long-term BCG immune therapy of superficial bladder tumours.

L Somogyi1, A Szántó, L Polyák, F Baranyay, M Drinóczy.   

Abstract

Long-term local BCG treatment of superficial bladder tumours is described and the 5-year results are reviewed. Complications of major significance in the course of immune therapy did not occur, loss due to death was not recorded. PPD skin test failed to furnish extra information regarding the biologic behaviour of the tumour. Annual repeats of the therapy promise better results than one single 6-week course.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624256     DOI: 10.1007/bf02549640

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

1.  Bacillus Calmette-Guerin immunotherapy.

Authors:  D L Lamm
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

Review 2.  An overview of intravesical therapy for superficial bladder tumors.

Authors:  H W Herr; V P Laudone; W F Whitmore
Journal:  J Urol       Date:  1987-12       Impact factor: 7.450

3.  Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.

Authors:  M S Soloway; A Perry
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

4.  Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ.

Authors:  A F Althausen; G R Prout; J J Daly
Journal:  J Urol       Date:  1976-11       Impact factor: 7.450

5.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

6.  Chemoimmune prophylaxis of superficial bladder cancer.

Authors:  H D Adolphs; H P Bastian
Journal:  J Urol       Date:  1983-01       Impact factor: 7.450

7.  Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers.

Authors:  A Morales; A S Pang
Journal:  J Urol       Date:  1986-01       Impact factor: 7.450

8.  Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.

Authors:  W D Winters; D L Lamm
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

9.  Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors.

Authors:  D L Lamm; S C Harris; R F Gittes
Journal:  Invest Urol       Date:  1977-03

10.  Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

Authors:  A Morales
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.